tiprankstipranks
Biocryst Pharmaceuticals (DE:BO1)
FRANKFURT:BO1

BioCryst Stock Price & Analysis

0 Followers

BO1 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€12.95
Volume0.00
Average Volume (3M)560.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€143.32M
Total Debt (Recent Filing)€32.63M
P/E RatioN/A
Beta1.49
Next EarningsNov 08, 2022
EPS Estimate-€0.28
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding185,945,016
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. Volume560
P/B Ratio-10.78
P/S Ratio14.29
P/CF RatioN/A
P/FCF Ratio-16.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside48.19% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering8


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

BO1 FAQ

What was BioCryst’s price range in the past 12 months?
Currently, no data Available
What is BioCryst’s market cap?
Currently, no data Available
When is BioCryst’s upcoming earnings report date?
BioCryst’s upcoming earnings report date is Nov 08, 2022 which is in 37 days.
    How were BioCryst’s earnings last quarter?
    BioCryst released its earnings results on Aug 04, 2022. The company reported -€0.326 earnings per share for the quarter, beating the consensus estimate of -€0.351 by €0.024.
      Is BioCryst overvalued?
      According to Wall Street analysts BioCryst’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does BioCryst pay dividends?
        BioCryst does not currently pay dividends.
        What is BioCryst’s EPS estimate?
        BioCryst’s EPS estimate is -€0.28.
          How many shares outstanding does BioCryst have?
          Currently, no data Available
          What happened to BioCryst’s price movement after its last earnings report?
          BioCryst reported an EPS of -€0.326 in its last earnings report, beating expectations of -€0.351. Following the earnings report the stock price went up 11.351%.
            Which hedge fund is a major shareholder of BioCryst?
            Among the largest hedge funds holding BioCryst’s share is Fisher Asset Management LLC. It holds BioCryst’s shares valued at 55M.

              ---

              BioCryst Stock Analysis

              Smart ScoreNeutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              7
              The BioCryst Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Biocryst Pharmaceuticals

              BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis